TRANSITIONAL CELL CARCINOMA

This adverse event was reported 1298 times

These drugs are most commonly taken by patients reporting TRANSITIONAL CELL CARCINOMA:

# Drug Count
0 TACROLIMUS 136
1 TACROLIMUS EXTENDED-RELEASE CAPSULES 126
2 TACROLIMUS OINTMENT 0.1% 126
3 PREDNISONE 121
4 METHOTREXATE SODIUM 115
5 MYCOPHENOLATE MOFETIL 108
6 MYCOPHENOLATE MOFETIL HYDROCHLORIDE 108
7 METHOTREXATE 103
8 CISPLATIN 79
9 ASPIRIN 71
See all common drugs associated with TRANSITIONAL CELL CARCINOMA

TRANSITIONAL CELL CARCINOMA is most prevalent among patients taking these drugs:

# Drug Count Frequency
0 ERDAFITINIB 18 0.0144
1 BACILLUS CALMETTE-GUERIN 8 0.0045
2 ENFORTUMAB VEDOTIN 27 0.0034
3 PEGFILGRASTIM 40 0.0033
4 SIROLIMUS 42 0.0031
5 ANTI-THYMOCYTE GLOBULIN (RABBIT) 14 0.0017
6 MYCOPHENILIC ACID 30 0.0014
7 PIOGLITAZONE 56 0.0013
8 EVEROLIMUS TABLETS 22 0.0013
9 BASILIXIMAB 15 0.0013
See all drugs enriched for association with TRANSITIONAL CELL CARCINOMA

These drug classes are most commonly taken by patients reporting TRANSITIONAL CELL CARCINOMA:

# Drug class Count
See all common drug classes associated with TRANSITIONAL CELL CARCINOMA

TRANSITIONAL CELL CARCINOMA is most prevalent among patients taking these drug classes:

# Drug class Count Frequency
See all drug classes enriched for association with TRANSITIONAL CELL CARCINOMA